TOT Biopharm International Co (HKSE:01875) Risk Assessment

View and export this data going back to 2019. Start your Free Trial

What is TOT Biopharm International Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of TOT Biopharm International Co is: High Risk: High uncertainty.

Competitive Comparison of TOT Biopharm International Co's Risk Assessment

For the Biotechnology subindustry, TOT Biopharm International Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TOT Biopharm International Co's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TOT Biopharm International Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where TOT Biopharm International Co's Risk Assessment falls into.

Save Embed

;

Save Embed

;

TOT Biopharm International Co (HKSE:01875) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

TOT Biopharm International Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of TOT Biopharm International Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

TOT Biopharm International Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TOT Biopharm International Co Ltd (HKSE:01875) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

120 Changyang Street, Suzhou Industrial Park, Suzhou, CHN, 215024

Website

https://www.totbiopharm.com.cn

TOT Biopharm International Co Ltd is a clinical-stage biopharmaceutical company dedicated to developing and commercializing oncology drugs and therapies for patients and their families as well as medical professionals. It has a pipeline of oncology drug candidates, which include monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). It generates revenues from Mainland China.

Executives

Center Laboratories, Inc.	2201 Interest of corporation controlled by you
Tricor Trust (hong Kong) Limited	2301 Trustee
Chengwei Evergreen Capital, Lp	2101 Beneficial owner
Center Laboratories Inc.	2101 Beneficial owner
Chengwei Evergreen Management, Llc	2201 Interest of corporation controlled by you
Suzhou Vivo Management Consulting Partnership (limited Partnership)
Vivo (suzhou) Health Industry Investment Fund (limited Partnership)
Vivo Capital Llc
Vivo Capital Viii, Llc
Vivo Capital Fund Viii, L.p.
Prime Success International Limited	2101 Beneficial owner
Advantech Capital Ii L.p.
Advantech Capital Ii Master Investment Limited
Advantech Capital Investment V Limited
Advantech Capital Partners Ii Limited

TOT Biopharm International Co Headlines

No Headlines